Table 5: Mitotic index and percentage of mitosis stages and mitotic aberrations in the root tip cells of A. cepa treated with organic extract derived at site 3.

Monthµg/mLMitotic index% P.% M.% A.% T.% T. A.% MCN% Bridge% Break% Lagging

NC0.04 ± 0.022.600.700.401.000.120.070.000.000.05
50.03 ± 0.020.700.400.900.300.300.040.020.000.14
August100.07 ± 0.032.702.200.902.100.50*0.300.100.000.10
150.06 ± 0.041.702.201.10*1.000.260.100.130.000.03
200.04 ± 0.021.601.400.701.000.160.100.030.000.03
250.03 ± 0.011.300.900.600.600.150.000.000.000.15
NC0.08 ± 0.066.001.600.901.400.670.100.080.200.42
50.04 ± 0.033.101.000.402.102.05*1.63*0.120.220.05
September100.03 ± 0.031.00*0.800.400.600.780.250.030.200.30
150.10 ± 0.103.303.201.202.001.800.001.00*0.600.20
200.00 ± 0.00*0.00*0.00*0.000.000.000.000.000.000.00
250.02 ± 0.01*1.00*0.10*0.000.700.120.000.000.100.02
NC0.08 ± 0.015.700.700.601.200.300.000.050.050.20
50.09 ± 0.013.801.600.802.900.600.000.000.50*0.10
October100.06 ± 0.051.90*0.700.402.700.280.100.030.050.10
150.03 ± 0.01*0.90*0.700.500.800.400.200.100.000.10
200.00 ± 0.00*0.00*0.000.000.000.000.000.000.000.00
250.01 ± 0.02*0.80*0.000.030.030.330.000.030.000.00

P.: prophase; M.: metaphase; A.: anaphase; T.: telophase; T.A.: total abnormalities; MCN.: micronucleus; NC.: negative control—DMSO; positive control = benzo(a)pyrene 10 µg/mL (mitotic index = 0.00*; % T.A. = 0.00; %) * ≤ 0.05.